

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 58

October 10, 2016

ISSUE No.  
**1505**

### IN THIS ISSUE

In Brief: Nitisinone (*Orfadin*) for Hereditary Tyrosinemia..... online only

## Important Copyright Message

### FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)  
or call customer service at: 800-211-2769

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 58 (Issue 1505)

October 10, 2016

### IN BRIEF

#### Nitisinone Oral Suspension (*Orfadin*) for Hereditary Tyrosinemia

The FDA has approved an oral suspension formulation of nitisinone (*Orfadin* – Sobi) for treatment of hereditary tyrosinemia type 1 (HT-1). *Orfadin* has been available in a capsule formulation in Canada since 1994 and in the US since 2002.

HT-1 is an autosomal recessive genetic disorder (estimated birth prevalence: 1:100,000) caused by mutations in the gene responsible for formation of fumarylacetoacetate hydrolase (FAH), which catalyzes the last step in tyrosine metabolism. FAH deficiency results in accumulation of upstream toxic metabolites, causing liver and kidney failure and developmental delays. Before the advent of liver transplantation, HT-1 was invariably fatal, usually as a result of liver failure or hepatocellular carcinoma. Quebec, Canada, which has a relatively high incidence of HT-1, has screened newborns for the disorder since 1970.<sup>1</sup>

Nitisinone inhibits 4-hydroxyphenylpyruvate dioxygenase, preventing formation of upstream toxic metabolites. Started in infancy in combination with a tyrosine- and phenylalanine-restricted diet, it can prevent development of liver and kidney disease and the need for liver transplantation.<sup>2-4</sup>

The recommended starting dosage of nitisinone is 0.5 mg/kg twice daily. The dosage can be increased after one month to 0.75 mg/kg twice daily (max 1 mg/kg twice daily). A 30-day supply of *Orfadin* suspension for a child weighing 10 kg costs \$13,623. *Orfadin* capsules can be opened and the contents can be mixed in a small amount of water, formula, or applesauce. A 30-day supply of *Orfadin* capsules (60 5-mg capsules) costs \$12,499.<sup>5</sup> ■

1. M Simoncelli et al. Cost-consequence analysis of nitisinone for treatment of tyrosinemia type 1. *Can J Hosp Pharm* 2015; 68: 210.
2. PJ McKiernan. Nitisinone in the treatment of hereditary tyrosinaemia type 1. *Drugs* 2006; 66:743.
3. S Gokay et al. The outcome of seven patients with hereditary tyrosinemia type 1. *J Pediatr Endocrinol Metab* 2016 September 28 (epub).
4. DC Bartlett et al. Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function. *J Inherit Metab Dis* 2014; 37:745.
5. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. September 5, 2016. Reprinted with permission by First Databank, Inc. All rights reserved. ©2016. [www.fdbhealth.com/policies/drug-pricing-policy](http://www.fdbhealth.com/policies/drug-pricing-policy).

**PRESIDENT:** Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School; **EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D.; **CONSULTING EDITORS:** Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

**CONTRIBUTING EDITORS:** Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; Jane P. Gagliardi, M.D., M.H.S., F.A.C.P., Duke University School of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Franco M. Muggia, M.D., New York University Medical Center; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; F. Estelle R. Simons, M.D., University of Manitoba; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

**MANAGING EDITOR:** Susie Wong; **ASSISTANT MANAGING EDITOR:** Liz Donohue; **EDITORIAL ASSISTANT:** Cheryl Brown

**EXECUTIVE DIRECTOR OF SALES:** Gene Carbona; **FULLFILLMENT AND SYSTEMS MANAGER:** Cristine Romatowski; **EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS:** Joanne F. Valentino; **VICE PRESIDENT AND PUBLISHER:** Yosef Wissner-Levy

Founded in 1959 by  
Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. is supported solely by subscription fees and accepts no advertising, grants, or donations. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

#### Subscription Services

**Address:**  
The Medical Letter, Inc.  
145 Huguenot St. Ste. 312  
New Rochelle, NY 10801-7537  
www.medicalletter.org

**Customer Service:**  
Call: 800-211-2769 or 914-235-0500  
Fax: 914-632-1733  
E-mail: custserv@medicalletter.org

**Permissions:**  
To reproduce any portion of this issue,  
please e-mail your request to:  
permissions@medicalletter.org

**Subscriptions (US):**  
1 year - \$129; 2 years - \$232;  
3 years - \$345. \$65 per year  
for students, interns, residents, and  
fellows in the US and Canada.  
Reprints - \$12 each.

**Site License Inquiries:**  
E-mail: info@medicalletter.org  
Call: 800-211-2769 ext. 315  
Special rates available for bulk  
subscriptions.

Get Connected:  

Copyright 2016. ISSN 1523-2859

